C ardiovascular therapies such as β-blockers, statins, and antiplatelet agents have been shown to improve outcomes after acute myocardial infarction (MI). 1 Performance measurement and quality improvement programs have traditionally focused on in-hospital use of these evidence-based therapies, leading to near ubiquitous prescription among eligible patients in the United States.
2 Despite their widespread prescription, several studies have demonstrated that downstream adherence to prescribed therapies is suboptimal. 3, 4 The reasons for low adherence rates are varied and involve complex relationships among the patient, provider, and society. [5] [6] [7] Healthcare delivery continues to evolve with the influx of newly insured patients and the consolidation of health systems. Consequently, measuring the quality of care provided to patients has become quite common and is often linked to provider compensation and reimbursement. 8, 9 With these and other efforts to increase value in health care, medication adherence is a natural candidate for quality measurement because poor adherence has been associated with higher costs and worse patient outcomes. [10] [11] [12] [13] Multifaceted programs used during patient admission have the potential to improve medication adherence. [14] [15] [16] Recognizing this, several hospital-based initiatives have targeted the transition of care from the inpatient to outpatient setting with the goal of improving patient medication adherence and clinical outcomes after discharge. 14 Healthcare systems now variably use discharge strategies that seek to identify barriers to medication adherence, provide patient education, and improve communication to outpatient providers. We hypothesize that the transition of care interventions across hospital systems may contribute to variation in downstream medication adherence among patients.
The objectives of this study were 2-fold: (1) determine whether hospital-level variation in 90-day medication adherence after MI exists among patients who are prescribed cardiac medications at index hospital discharge; and (2) compare 2-year outcomes among hospitals with high, moderate, or low medication adherence after discharge, adjusting for differences in patient case mix and hospital characteristics.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Design and Population
The ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines) is an ongoing quality improvement registry of consecutive patients with a primary diagnosis of either ST-segment elevation MI (STEMI) or non-STEMI (NSTEMI) who are treated at participating hospitals across the United States. The institutional review board of each reporting hospital approved participation in the ACTION Registry-GWTG or determined a waiver of the need for review. Detailed clinical data are abstracted from the medical record and include demographics, prior medical history, in-hospital procedures and therapies, clinical events before discharge, and medications prescribed at discharge (https://www.ncdr.com/webncdr/action/home/ datacollection). The type and quality of data collected have been previously described. [17] [18] [19] [20] Because patient information was collected without unique patient identifiers in the ACTION Registry-GWTG, we used 5 indirect identifiers in combination (date of birth, sex, hospital identification, date of admission, date of discharge) to link patients >65 years of age with Medicare claims data. 20 This data linkage was supported by the Centers for Education and Research on Therapeutics grant (U19HS021092) from the Agency for Healthcare Research and Quality. The Duke University Medical Center Institutional Review Board granted a waiver of informed consent and authorization for this study, and all analyses were conducted by the Duke Clinical Research Institute.
Clinical Perspective
What Is New?
• In this study of 19 704 elderly patients with acute myocardial infarction across 347 hospitals, we used prescription drug coverage claims to assess medication adherence on a hospital level and found variation in 90-day adherence among hospitals: β-blockers (59% to 75%), statins (55% to 69%), thienopyridines (64% to 77%), and angiotensinconverting enzyme inhibitors/angiotensin receptor blockers (57% to 69%).
• Hospitals with higher medication adherence were associated with lower downstream major adverse cardiovascular events (adjusted hazard ratio, 0.88; 95% confidence interval, 0.80-0.96), as well as death or readmission (hazard ratio, 0.90; 95% confidence interval, 0.85-0.96) after adjusting for differences in patient and hospital characteristics.
What Are the Clinical Implications?
• Hospitals have the capacity to influence a patient's adherence to secondary prevention cardiac medications, thereby also potentially impacting longterm patient outcomes.
• The transition from hospital to home represents a key opportunity to implement policies that address barriers to medication adherence. • Further work is needed to identify best hospital discharge practices that promote medication adherence and provide a uniform and seamless transition home. 
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Study Population
We included all patients with MI (STEMI or NSTEMI) in the ACTION Registry-GWTG database from January 2, 2007, to October 1, 2010, who were enrolled in the Centers for Medicare & Medicaid (CMS) Part D prescription coverage plan (n=23 475) ( Figure 1 ). We excluded patients treated with coronary artery bypass graft surgery (n=1610), those not discharged to home (n=353), and those who did not survive to 90 days after discharge (n=1191). We also excluded patients who were discharged on none of the following cardiovascular medications: β-blockers, statins, thienopyridines, and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs) (n=197). To assess hospital variation in 90-day adherence, we examined hospitals with ≥25 opportunities for adherence (ie, 1 opportunity for each evidence-based medication) among MI discharges. We did not include sites with <25 opportunities (112 sites) because we presumed that with such low volumes these sites were not routinely treating patients with acute MI (n=420). In addition, estimates for the smaller sites would be subject to larger sampling variation and noise. Our final study population was comprised of 19 704 patients at 347 hospitals.
Statistical Analysis
The primary outcome of interest was medication adherence at 90 days after discharge from a participating hospital after acute MI. We defined adherence as >80% proportion of days covered (PDC) individually for β-blockers, statins, ACEIs/ARBs, and thienopyridines; adherence to each medication was only assessed among patients who were prescribed this medication at hospital discharge. The use of a dichotomous variable of PDC >80% is consistent with previously used methods. 21, 22 We used logistic regression with random intercepts for hospitals and Spearman correlations to assess whether adherence to specific medications varied together according to a hospital and if 90-day medication adherence correlated with 1-year adherence. To assess for hospital-level composite adherence of the 4 cardiovascular medications, we included a fixed effect for medication type, included a random effect for hospital, and estimated the hospital-specific odds ratio (OR) for composite adherence. We examined the distribution of hospitalspecific OR and found that the 25th percentile corresponded to a >10% decrease in odds and the 75th percentile corresponded to a >12% increase in odds for adherence. Because we felt these were meaningful cutoffs, we used percentiles of ORs to classify hospitals into high (>75th percentile), moderate (25th-75th percentiles), and low (<25th percentile) adherence ( Figure I in the online-only Data Supplement). Patient and hospital characteristics were compared among the high-, moderate-, and low-adherence hospitals using χ 2 testing for categorical variables (if the sample size was not sufficient, then exact test was used) and Wilcoxon rank-sum testing for continuous variables. We also assessed medication adherence across hospitals at 1 year after discharge.
Next, we compared 2-year major adverse cardiovascular events (MACE) and death or all-cause readmission risk among hospitals with high, moderate, or low 90-day medication adherence. Long-term analysis of MACE and death or allcause readmission included only those events that occurred 90 days after discharge because we felt that early events may affect 90-day adherence. MACE included death, as well as readmission for MI, stroke, or revascularization within 2 years after discharge. Kaplan-Meier curves were generated to estimate the probability of each outcome by hospital adherence group, and the log-rank test was used to assess whether the differences between the curves were statistically significant. Cox proportional hazards modeling was performed to examine the association between hospital adherence group and each outcome, using robust standard errors to account for the clustering of patients within hospitals. The model was adjusted to account for differences in case mix. Variables in the model included demographics (age, sex, race, length of stay, and body mass index), indicators of socioeconomic status (derived from patient zip codes and US Census data: percentage of patients ≥25 years of age with ≥4 years of college, percentage of patients ≥25 years of age with high school diploma, percentage of white-collar workers, median estimate household income, median home value), 23 additional insurance besides Medicare (private/health maintenance organization), comorbidities (tobacco use, hypertension, dyslipidemia, hemodialysis, diabetes mellitus, peripheral artery disease, and prior history of MI, heart failure, percutaneous coronary intervention, coronary artery bypass graft, and stroke), STEMI or STEMI equivalent on arrival, transfer-in status, cardiac catheterization in ≤24 hours of arrival, in-hospital percutaneous coronary intervention, left ventricular ejection fraction, endstage renal disease, baseline hemoglobin, in-hospital heart failure complication, in-hospital major bleeding, and any blood transfusion. The following hospital characteristics were also included: geographic region, hospital type (catheterization laboratory only, percutaneous coronary intervention capability only, and coronary artery bypass graft capability), teaching hospital (academic and nonacademic), and hospital bed size.
All analyses were performed using the SAS software package version 9.4 (SAS Institute).
RESULTS
Among patients discharged to home after an acute MI, use of evidence-based secondary prevention therapy prescription was high, with 96% discharged on β-blockers, 89% on a statin, 84% on a thienopyridine, and 76% on ACEIs/ARBs among patients with no documented contraindications to therapy. Nonetheless, by 90 days after discharge, only 68% of patients prescribed β-blocker therapy at discharge remained adherent. Similarly, only 63%, 64%, and 72% of those discharged on statins, ACEIs/ARBs, and thienopyridines, respectively, remained adherent by 90 days. It is important to note that there was significant interhospital variation in 90-day adherence to these therapies. As seen in Figure 2 , the probability of adherence varied widely (P<0.001). Hospital-level adherence rates for various therapies was correlated; hospitals with high adherence to 1 medication were also likely to demonstrate high adherence to another medication (β-blocker and statin: correlation coefficient [r]=0.42; β-blocker and ACEI/ARB: r=0.35; β-blocker and thienopyridine: r=0.44' statin and ACEI/ ARB: r=0.41; statin and thienopyridine: r=0.34, ACEI/ ARB and thienopyridine: r=0.29; Figure II in the onlineonly Data Supplement). In addition, we found that hos- 
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pital adherence at 90 days was associated with higher hospital adherence at 1 year (Spearman's rho=0.63). By 1 year, adherence had decreased ≈8% across all medications: 61% of patients remained adherent to β-blockers, 55% to statins and ACEIs/ARBs, and 64% to thienopyridines. Hospitals were divided into those with high probability (OR, 1.12-1.45; 86 hospitals; 6570 patients), moderate probability (OR, 0.90-1.12; 175 hospitals; 9249 patients), or low probability (OR, 0.57-0.90; 86 hospitals; 3885 patients) of 90-day medication adherence. At 90 days after discharge, adherence rates to secondary prevention medications for each group are shown in Table 1 . We observed that hospitals with high 90-day medication adherence were less likely to be located in the Southern United States (25%) than hospitals with low and moderate adherence (51% and 58%, respectively). High-adherence hospitals were more often academic centers (35%) compared with moderate-(23%) and low-adherence (25%) hospitals. High-adherence hospitals were also substantially larger in terms of higher bed capacity and had ≈2 times as many transfer-in patients than hospitals with low 90-day medication adherence (Table 1) . Table 2 compares patient case-mix and in-hospital treatment patterns among these hospital groups. Compared with other hospitals, those with low 90-day medication adherence had higher proportions of patients who were female, were of nonwhite race, had less educational achievement, and had a lower household income. Patients treated at hospitals with low medication adherence were more likely to present with NSTEMI than STEMI and to have a prior history of cardiovascular disease (prior MI, percutaneous coronary intervention, stroke, or peripheral artery disease) or cardiovascular risk factors (diabetes mellitus, hypertension, tobacco use) than patients treated at hospitals with moderate or high medication adherence. Although rates of STE- MI reperfusion were similar among hospitals, hospitals with low 90-day medication adherence were less likely to revascularize patients presenting with NSTEMI. The incidence of in-hospital heart failure and major bleeding was higher among patients treated in low-adherence hospitals. The median length of stay was 4 days for lowand moderate-adherence hospitals, whereas the median length of stay was 3 days for high-adherence hospitals. High-adherence hospitals more often referred patients for cardiac rehabilitation after discharge compared with moderate-and low-adherence hospitals: 78% (high adherence) versus 75% (moderate adherence) versus 64% (low adherence), respectively (P<0.001).
As seen in Figure 3 , the unadjusted cumulative incidence of MACE at 2 years was lower among hospitals with higher 90-day medication adherence (27.5%) compared with moderate-(31.0%) and low (35.3%)-adherence hospitals (log-rank P<0.0001). After adjusting for differences in hospital characteristics and patient case mix, patients at high-adherence hos- 
pitals remained less likely to experience MACE (hazard ratio, 0.88; 95% confidence interval, 0.80-0.96).
The difference in MACE between moderate-and lowadherence hospitals was attenuated but remained significant (hazard ratio 0.91; 95% confidence interval, 0.83-1.0; Figure 4) . Two-year mortality rates differed among high-(16.8%), moderate-(19.1%), and low (21.1%)-adherence groups ( Figure 5 ), but there was no difference between the groups after multivariate adjustment (Figure 4) . Nevertheless, we found lower rates of death or all-cause readmission among high-adherence hospitals (56.0%) compared with hospitals that had moderate (59.4%) and low (64.1%) adherence (log-rank P value <0.001; Figure 6 ) that persisted after multivariable adjustment (hazard ratio, 0.90; 95% confidence interval, 0.85-0.96; Figure 4) . Similarly, patients at moderateadherence hospitals were also less likely to experience these adverse outcomes compared with low-adherence hospitals (hazard ratio, 0.93; 95% confidence interval, 0.87-0.99).
DISCUSSION
Our study found that adherence to prescribed evidence-based cardiovascular medications after MI was suboptimal. By 90 days, adherence rates ranged from 63% to 72% for key secondary prevention medications, varying significantly across hospitals, and adherence rates further declined by 1 year (55% to 64%). 
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Relative to patients treated at low-adherence hospitals, those treated at high and moderate 90-day adherence centers had lower observed MACE and death or readmission rates that persisted after adjustment for hospital characteristics and patient case mix.
We observed a decline in overall medication adherence as early as 90 days after discharge for an MI, with marked variation in adherence rates across hospitals. Hospital adherence groups differed in several patient characteristics, as well as sociodemographic factors. Prior work has found factors such as nonwhite race and comorbidities to be independently associated with poorer adherence. 3 In particular, patients who are nonadherent more often have lower health literacy, lower perceived quality of life, and higher rates of depression. 4 Not surprisingly, we found these high-risk characteristics of nonadherence to be more prevalent in low-adherence hospitals. We would expect that these differences in patient case mix between hospital groups would contribute to adherence variation.
It is important to note that after accounting for patient case mix, hospital-level variation in medication adherence continues to persist in community practice. Highadherence hospitals were typically larger and academic centers-2 factors that may have increased the resources available to invest in the development of systematic and comprehensive inpatient and discharge practices that can potentially improve adherence after discharge. For example, the use of a tailored medication management system by Veteran's Administration hospitals led to improved patient adherence to anticoagulants (risk ratio, 1.31; 95% CI,1.16-1.47), with a positive correlation between duration of follow-up and long-term adherence. 22 Our findings demonstrate that hospitals with higher 90-day medication adherence were associated with improved MACE and readmission risk at 2 years. Mortality was not significantly different, suggesting that the difference in outcomes lies in preventing nonfatal events and unscheduled contact with the healthcare system. The relationship between medication adherence after discharge and downstream outcomes is complex and may include several factors. For example, improvement in outcomes may be attributed to the benefits associated with the medication. [24] [25] [26] [27] [28] [29] However, in addition to the cardioprotective benefits of the medications, other factors that contribute to downstream outcomes include patient burden of illness. When these differences were adjusted for via multivariate modeling, we found that the higher probability of cardiovascular events among low-adherence patients was attenuated but did not fully resolve, suggesting that factors beyond patient case mix may contribute to outcomes at the hospital level. These factors may be on a provider, health system, or societal level.
Unlike MACE and readmission risk, we did not find any association between hospital adherence and longterm mortality. The reasons for this lack of association are unclear but may be explained by the age of our study population (median age 75 years). The increased baseline cardiovascular risk in an elderly population may mitigate the magnitude of association between adherence and survival noted in prior studies. 24, 25 Although medication adherence is especially impactful on highrisk patients, adherence remained suboptimal even among high-adherence hospitals and may be below the level needed to influence survival among this subgroup. It is also important to note that the relationship between adherence and long-term mortality has not been fully elucidated in real-world patient populations and may be attributed to the healthy adherer bias. 25 High-adherence hospitals may be associated with the overall higher quality of services provided. One marker of high quality is a hospital's adherence to evidence-based care processes associated with improved clinical outcomes. 30, 31 We found that high-adherence hospitals performed better than low-adherence hospitals on metrics such as time from arrival to ECG and time from arrival to cardiac catheterization. Hospitals that achieved high performance in both guideline adherence and issues of patient safety (ie, reductions in excess dosing of anticoagulants) 32 have been associated with a trend toward lower risk-adjusted mortality. 33 Assessing differences in hospital quality has become more challenging because most hospitals now routinely achieve high performance on traditional evidence-based process measures.
2 As novel measures are considered, medication adherence on a hospital level may provide a new paradigm to assess quality. Although medication adherence has traditionally been considered a patient's responsibility, our work suggests that hospitals have the capacity to impact downstream patient adherence. The transition from hospital to home has been identified as an important period that may directly influence patients' risk of long-term cardiovascular events. [34] [35] [36] Interhospital differences in discharge practices, such as early physician follow-up and cardiac rehabilitation referral, may contribute to variation in hospital-level medication adherence and subsequent differences in cardiovascular events noted in our study. For example, the routine use of a cardiovascular team-based model has been associated with a reduction in readmissions; this model includes pharmacists, advanced care practitioners, social workers, and discharging physician. [37] [38] [39] Similarly, transition of care models with early intense monitoring after discharge have been associated with reduced all-cause hospitalization and 6-month mortality. 40 Medication adherence has been associated with improved outcomes, so hospitals and healthcare systems that enact policies promoting adherence may provide higher quality care. We believe that opportunities to assess hospital-level medication adherence through the use of prescription claims databases will continue
to develop as administrative and clinical databases become more comprehensive and allow for appropriate adjustment of patient-and hospital-level differences in patient case mix and resource availability. There is wide recognition that medication adherence is critical, but there can be a disconnect between provider and patient perceptions of factors contributing to (or impeding) adherence. 41, 42 The positive impact of high adherence on patient outcomes only reinforces the need for healthcare systems and providers to remain proactive as advocates for their patients and promote adherence to prescribed therapies.
Future Steps
We found that healthcare system factors may contribute to a patient's likelihood of medication adherence and subsequent clinical outcomes. These factors may include providing patient education, behavioral support, provider communication, and access to care. Various interventions have had success with integrating evidence-based practices, such as screening for patient barriers to adherence and ensuring better continuity of care with outpatient physicians. For example, successful disease management programs are comprehensive and include components such as telephone follow-up, self-management, dietary advice, exercise recommendations, medication review, and social support. 40 Because there are numerous potential intervention targets, it is not surprising that there is wide variability across centers in the patient experience at discharge.
We propose a comprehensive assessment of current practices among a diverse group of hospitals. The next step should be to understand the effect of these practices on patient medication adherence and subsequent clinical outcomes, which is critical because resources are limited. Furthermore, the likelihood of sustaining an intervention is often related to the return on investment (eg, improved outcomes and cost savings). Strategies that are most scalable across healthcare systems should be identified and would provide the basis for the development of best practices that can be disseminated broadly across hospital networks. Policies currently in place penalize hospitals for avoidable readmissions. 43 Although controversial, the intended purpose is to address hospital factors that can lead to poor outcomes. Conversely, hospitals should be recognized for creative and effective efforts that promote improved patient outcomes. Our work demonstrates that hospitals and healthcare systems have the capacity to positively impact medication adherence, although the best way to accomplish this task remains unclear.
Limitations
Our study should be interpreted in light of several limitations. First, the use of PDC as a measure of adherence has been validated, but we cannot determine whether medication dispensing equated with patients actually taking the medications. Second, the number of hospital factors in our analysis was limited, and we do not capture data on specific practices implemented at each hospital. We have attempted to account for these differences through multivariate modeling. However, as in any observational analysis, we are unable to account for unmeasured confounders that may influence outcomes. For example, resources available to address issues of mental illness, poverty, and poor social support vary across communities and likely influence a hospital's effectiveness in achieving medication adherence. Third, we do not have data on adherence among patients not enrolled in Medicare Part D or on alternate prescription coverage among nonenrollees. Prior work has demonstrated that Part D enrollees are more often nonwhite and have a higher comorbidity burden compared with nonenrollees. 44 The use of evidence-based medications on discharge has been shown to be similar between enrollees and nonenrollees, but the differences in patient characteristics may also influence long-term adherence and outcomes. Finally, we did not collect information on processes after discharge that may influence medication adherence. Therefore, we cannot account for unmeasured factors that may contribute to differences we observed in long-term outcomes.
Conclusions
Health care is facing challenges because of new regulatory requirements, an aging population requiring more complex care, and alternative payment models that emphasize value-based purchasing. 45, 46 We found that US hospitals vary in downstream medication adherence to cardiac therapies after discharge for an MI. Patient adherence is a critical component of an evolving healthcare system that is now prioritizing quality of care over traditional fee for service. We believe an understanding of factors associated with adherence on a hospital level and a patient level provides a novel framework on which to further engage with the issues of poor medication adherence in health care. The transition of care from the inpatient setting to a patient's home is a key opportunity for hospital systems and accountable care organizations to address (on a systems level) factors that impact adherence and subsequent outcomes.
